Research Finds MyoPro® Delivers Meaningful Improvements in Motor Function for Brain Injury Patient

Stock Information for Myomo Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Myomo Inc.

Myomo Appoints Heather Getz to its Board of Directors
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.